Freedom of Information request on the death's reported following the COVID-19 vaccines for children (FOI 22/372)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-14-february-2022/freedom-of-information-request-on-the-deaths-reported-following-the-covid-19-vaccines-for-children-foi-22372
FOI 22/372
16th February 2022
Dear
Thank you for your Freedom of Information email dated 19 January 2022, where you requested the following:
The number of child deaths after having had the COVID-19 vaccine and the number of unborn baby deaths in the womb due to mothers having taken the COVID-19 vaccine.
Regarding your request, the MHRA only holds reports of suspected adverse drug reactions in relation to the COVID-19 vaccines and does not hold a comprehensive list of deaths post vaccination. For the information requested please speak to the Office of National Statistics (ONS).
Since the launch of the COVID-19 immunisation campaign we have been proactively monitoring the safety of all approved COVID-19 vaccines for near real-time safety monitoring at population level. Our adverse reaction assessment report can be found here: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division